Nanoemulsions as versatile formulations for paclitaxel delivery: Peroral and dermal delivery studies in rats

Journal of Investigative Dermatology

Volumn 127, Issue 1, 2007, Pages 154-162

  Khandavilli, Sateesh ^a   Panchagnula, Ramesh ^b  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; GLYCOPROTEIN P; LABRASOL; M 1944CS; PACLITAXEL; SURFACTANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; EMULSION; IN VIVO STUDY; LIPOPHILICITY; MOLECULAR WEIGHT; NANOEMULSION; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN PENETRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; EMULSIONS; NANOPARTICLES; PACLITAXEL; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; SKIN; SOLUBILITY;

EID: 33845798299     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700485     Document Type: Article

References (44)

1. Alkan-Onyuksel H, Ramakrishnan S, Chai HB, Pezzuto JM (1994) A mixed micellar formulation suitable for parenteral administration of taxol. Pharm Res 11:206-12
2. 2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. Cancer Res 58:241-7
3. Baldwin JR, Carrano RA, Imondi AR (1984) Penetration of trolamine salicylate into skeletal muscle of pig. J Pharm Sci 73:1002-4
4. Behl C, Char H, Patel S, Mehta D, Piemontere D, Malick A (1993) In vivo and in vitro skin uptake and permeation studies: critical considerations and factors which affect them. In: Topical drug bioavailability, bioequivalence, and penetration (Shah VP, Maibach HI, eds) New York: Plenum Press, 225-59
5. Bittner B, Guenzi A, Fullhardt P, Zuercher G, Gonzalez RC, Mountfield RJ (2005) Improvement of the bioavailability of colchicine in rats by coadministration of D-alpha-tocopherol polyethylene glycol 1,000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid. Arzneim Forsch 52:684-8
6. Bogman K, Erne-Brand F, Alsenz J, Drewe J (2003) The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J Pharm Sci 92:1250-61
7. Chang T, Benet LZ, Hebert MF (2005) The effect of water-soluble vitamin E on cyclosporine. Pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 59:297-303
8. Cornaire G, Houin G, Arellano C, Cloarec A (2004) Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 278:119-31
9. Dawson M, Brooks PM, Vine JH, Watson TR MCGee CM, Nash P (1988) The disposition of biphenylacetic acid following topical administration. Eur J Clin Pharmacol 33:639-42
10. Dhanikula AB, Panchagnula R (1999) Localized paclitaxel delivery. Int J Pharm 183:85-100
11. Dhanikula AB, Panchagnula R (2004) Development and characterization of biodegradable chitosan films for local delivery of paclitaxel. AAPS J 6: article 27 (doi:10.1208/aapsj. 060327)
12. Dhanikula AB, Panchagnula R (2005a) Preparation and characterization of water soluble prodrug, liposomes and micelles of paclitaxel. Curr Drug Deliv 2:75-92
13. Dhanikula AB, Singh DR, Panchagnula R (2005b) In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of paclitaxel: gel, film, prodrug liposomes and micelles. Curr Drug Deliv 2:35-44
14. Dintaman JM, Silverman JA (1999) Inhibition of p-glycoprotein by D-a-tocoferyl polyethylene glycol 1,000 succinate (TPGS). Pharm Res 16:1550-6
15. Frye M, Gardner C, Li ER, Arnold I, Watt FM (2003) Evidence that Myc activation depletes the epidermal stem cell compartment by modulating adhesive interactions with the local microenvironment. Development 130:2793-808
16. Gao P, Rush BD, Pfund WP, Huang T, Bauer JM, Morozowich W et al. (2003) Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci 92:2386-98
17. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590-8
18. Gupta RR, Jain SK, Varshney M (2005) AOT water-in-oil microemulsions as a penetration enhancer in transdermal drug delivery of 5-fluorouracil. Colloid Surface B 41:25-32
19. He L, Wang G, Zhang Q (2003) An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile. Int J Pharm 250:45-50
20. Higaki K, Asai M, Suyama T, Nakayama K, Ogiwara K, Kimura T (2002) Estimation of intradermal disposition kinetics of drugs: II. Factors determining penetration of drugs from viable skin to muscular layer. Int J Pharm 239:129-41
21. Kasim NA, Whitehouse M, Ramachandran C, Barnejo M, Lennernas H, Hussain AS et al. (2003) Molecular properties of WHO essential drugs and provisional biopharmaceutic classification. Mol Pharm 1:85-96
22. Kimura Y, Aoki J, Kohno M, Ooka H, Tsuruo T, Nakanishi O (2002) P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumour efficacy of orally administered paclitaxel. Cancer Chemother Pharmacol 49:322-8
23. Kreilgaard M (2002a) Influence of microemulsions on cutaneous drug delivery. Bull Tech Gattefosse 95:79-100
24. Kreilgaard M (2002b) Influence of microemulsions on cutaneous drug delivery. Adv Drug Del Rev 54:S77-98
25. Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K et al. (2003) Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol 120:476-82
26. 2-terminal kinase (JNK/SAPK). J Biol Chem 273:28253-60
27. Marty JP, Guy RH, Maibach HI (1989) Percutaneous penetration as a method of delivery to muscle and other tissues. In: Percutaneous absorption: mechanisms, methodology, drug delivery (Bronaugh RL, Maibach HI, eds). New York: Marcel Dekker, 511-29
28. Nokhodchi A, Shokri J, Dashbolaghi A, Hassan-Zadeh D, Ghafourian T, Barzegar-Jalali M (2003) The enhancement effect of surfactants on the penetration of lorazepam through rat skin. Int J Pharm 250:359-69
29. Panchagnula R, Desu H, Jain A, Khandavilli S (2004a) Effect of lipid bilayer alteration on transdermal delivery of high molecular weight and lipophilic drug: studies with paclitaxel. J Pharm Sci 93:2177-83
30. Panchagnula R, Desu H, Jain A, Khandavilli S (2005) Feasibility studies of dermal delivery of paclitaxel with binary combinations of ethanol and isopropyl myristate: role of solubility, partitioning and lipid bilayer perturbation. IL Farmaco 59:839-42
31. Panchagnula R, Khandavilli S (2004b) In vitro and in vivo evaluation of gel formulation for the transdermal delivery of naloxone. Pharm Ind 66:228-33
32. Prasad YVR, Puthli SP, Eaimtrakarn S, Ishida M, Yoshikawa Y, Shibata N et al. (2003) Enhanced intestinal absorption of vancomycin with labrasol and D-a-tocopheryl PEG 1,000 succinate in rats. Int J Pharm 250:181-90
33. Radermacher J, Jentsch D, Scholl MA, Lustinetz T, Frolich JC (1991) Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease. Br J Clin Pharmacol 31:537-41
34. Singh P, Roberts M (1996) Local deep tissue penetration of compounds after dermal application: structure-tissue penetration relationships. J Pharmacol Exp Ther 279:908-17
35. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF et al. (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-5
36. Straubinger R, Sharma A, Murray M, Mayhew E (1993) Novel taxol formulations: Taxol-containing liposomes. J Natl Cancer Inst Monogr 15:69-78
37. Straubinger RM (1995) Biopharmaceutics of paclitaxel (Taxol): formulation, activity, and pharmacokinetics. In: Taxol: science and applications (Suffness M, ed.) New York: CRC Press, 237-58
38. Tenjarla S (1999) Microemulsions: an overview and pharmaceutical applications. Crit Rev Ther Drug Carrier Syst 16:461-521
39. Vaddi HK, Wang LZ, Ho PC, Chan SY (2001) Effect of some enhancers on the permeation of haloperidol through rat skin in vitro. Int J Pharm 212:247-55
40. Varma MVS, Ashokraj Y, Dey CS, Panchagnula R (2003) P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 48:347-59
41. Varma MVS, Panchagnula R (2005) Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 25:445-53
42. Woo JS, Lee CH, Shim CK, Hwang S-J (2003) Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res 20:24-30
43. Wu SH, Hopkins WK (1999) Characteristics of D-a-tocopheryl PEG 1,000 succinate for applications as an absorption enhancer in drug delivery systems. Pharm Technol 23:52-60
44. Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A et al. (1999) Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. J Pharm Sci 16:1812-7